Company news
Xoma Royalty Corporation (NASDAQ:XOMA) news
Every Xoma Royalty Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 8, 2023
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
June 22, 2023
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2023
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
May 9, 2023
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
March 30, 2023
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
March 9, 2023
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 6, 2023
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
January 4, 2023
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
November 3, 2022
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
August 4, 2022
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events
May 5, 2022
XOMA Announces Evolution of Company Leadership and Succession Planning
December 16, 2021
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
November 4, 2021
XOMA Announces Heather L. Franklin Joins its Board of Directors
August 10, 2021
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events
August 5, 2021
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
July 15, 2021
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events
May 6, 2021
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
May 3, 2021
XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters’ Option
April 12, 2021
XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock
April 5, 2021
XOMA Announces Approval of First Preferred Stock Dividend
March 22, 2021
XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights
March 10, 2021
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering
December 21, 2020
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock
December 10, 2020
XOMA Announces Offering of Series A Cumulative Perpetual Preferred Stock
December 10, 2020
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development
November 16, 2020
XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
November 11, 2020
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
November 3, 2020
XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer
October 28, 2020
XOMA Earns $1.9 Million Associated with Two Partner Developments
October 14, 2020
XOMA Reports Second Quarter 2020 Financial Results
August 6, 2020
XOMA Announces Natasha Hernday Joins its Board of Directors
July 1, 2020
XOMA Reports First Quarter 2020 Financial Results and Provides COVID-19 Business Update
May 5, 2020
XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights
March 10, 2020
XOMA Announces Closing of Rights Offering
December 20, 2019
XOMA Announces Commencement of Rights Offering
December 2, 2019
XOMA Announces Proposed Rights Offering
November 19, 2019
CORRECTING and REPLACING -- XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results
November 5, 2019